Press Release

Oncotarget: Comparisons between different anti-mitotics in triple negative breast cancer

FOR IMMEDIATE RELEASE
2021-10-29

Oncotarget published "Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer" which reported that these data provide extensive evidence to demonstrate that KIF11 inhibitors showed pronounced antitumor activity, acting in key points of tumorigenesis and cancer progression in in vivo xenograft model of triple negative breast cancer, like down-regulation of KIF11 and ALDH1-A1.

These results suggest that the use of a MAP inhibitor in breast cancer regimen treatment could be a promising strategy to keep antitumoral activity reducing the side effects.

Dr. Sônia Nair Báo and Dr. José Raimundo Corrêa from The University of Brasília said, "Triple-negative breast cancer (TNBC) constitutes a very aggressive subtype that accounts for approximately 12–18% of breast cancer patients."

The stratification of patients according to their receptor status is still a cost-effective, rapid and easy way to assess the suitability of breast cancer patients to targeted treatments. Since TNBCs patients do not express estrogen receptor, progesterone receptor and human epidermal growth factor receptor, they are not eligible for hormone or HER2 target therapies, and so, few chemotherapy options remain available for them.

The resulting complex abolishes cell's ability to use its cytoskeleton in a flexible way, inducing mitotic arrest and leading to cell death in a subset of the arrested population. However, since this dynamic instability of microtubules of shortening and lengthening is essential for important cell functions besides cell division, like cargo transportations, many side effects come along with the administration of this drug.

Considering the already mentioned correlation between high levels of KIF11 and worse prognostic in different cancer types, several inhibitors for this motor protein are currently being studied in clinical trials. However, despite the great results obtained in preclinical studies using KIF11 inhibitors there are still some problems being faced in clinics, like the occurrence of neutropenia being the dose-limiting factor and the emergence of resistance.

The Báo/Corrêa Research Team concluded in their Oncotarget Research Output, "our study provides extensive evidence to demonstrate that KIF11 inhibitor 4bt showed pronounced antitumor activity, acting in key points of tumorigenesis and cancer progression in in vivo xenograft model of triple negative breast cancer. These considerations imply that KIF11 inhibitors may represent a promising strategy to be used as adjuvant therapy in breast cancer treatment regimen and may improve TNBC patients' outcomes showing considerably fewer side effects. Furthermore, this inhibitor has shown other interesting roles for tumor inhibition, like down-regulation of KIF11 and ALDH1-A1, particularly when combined with existing treatments."

DOI - https://doi.org/10.18632/oncotarget.28068

Full text - https://www.oncotarget.com/article/28068/text/

Correspondence to - Sônia Nair Báo - snbao@unb.br and José Raimundo Corrêa - correa@unb.br

Keywords - prostate cancer, castration resistance, detoxification, UDP-glucose dehydrogenase, patient-derived xenografts

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105